Skip to main content

Table 3 Number of subjects with abnormal and normal responses to ACTH stimulation tests performed every 2 weeks

From: Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-controlled, crossover study

Treatment sequence Subjects, n Period Subjects with abnormal response to ACTH stimulation, n
1 2 3 Test 1 Test 2a Test 3b
    (N = 37) (N = 18) (N = 2)
A 5 Placebo 2.5 mg 10 mg 3 0 0
B 5 2.5 mg 5 mg 20 mg 5 0 0
C 5 5 mg 10 mg 40 mg 4 1 1c
D 5 10 mg 20 mg 60 mg 5 1 0
E 6d 20 mg 40 mg Placebo 0 0 0
F 5 40 mg 60 mg 2.5 mg 0 0 0
G 6d 60 mg Placebo 5 mg 1 0 0
Total 37   18 2 1
  1. Doses shown correspond to the daily prednisone dose administered for 7 days in each treatment period
  2. ACTH adrenocorticotropic hormone
  3. aSubjects who failed Test 1 were re-tested 2 weeks later
  4. bSubjects who failed Test 2 were re-tested 2 weeks later
  5. cReturned to normal on Study Day 138
  6. dOne subject in sequence E and one in sequence G discontinued the study during Period 2 and were replaced following approval by the study statistician, therefore n = 6 in these groups for this analysis